Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality by Svein G. DahlClinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality by Svein G. Dahl

Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical Reality

bySvein G. DahlEditorLars F. Gram

Paperback | December 10, 2011

Pricing and Purchase Info

$210.21 online 
$219.50 list price
Earn 1,051 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


This volume collects the invited lectures and some selected contributions presented at the 5th International Meeting on Clinical Pharmacology in Psychiatry, which was held 26-30 June 1988 at the University of Troms0, Norway. The 24 h of daylight at the northernmost university in the world al­ lowed for long, pleasant and productive sessions. The title of the conference as well as a number of the topics covered represent a continuation of four previous conferences, the first held in Chicago in 1979 and organized by the late Earl U sdin and colleagues. The earlier conferences have been documented in Clinical Pharmacology in Psychiatry, edited by E. Usdin (Elsevier, New York, 1981), Clinical Pharmacology in Psychiatry. Neuroleptic and Antidepressant Research, edited by E. Usdin, S. G. Dahl, L. F. Gram and o. Lingjrerde (Macmillan Publishers Ltd., London, 1981), Clinical Pharmacology in Psychiatry. Bridging the Experimental-Therapeutic Gap, edited by LF. Gram, E. Usdin, S.G. Dahl, P. Kragh-Sorensen, P. L. Morselli and F. Sjoqvist (Macmillan Publishers Ltd., London, 1983), and Clinical Pharmacology in Psychiatry. Selectivity in Psychotropic Drug Action - Promises or Problems? edited by S. G. Dahl, L.F. Gram, S.M. Paul and W.Z. Potter (Psychopharmacology Series 3, Springer, Heidelberg, 1987).
Title:Clinical Pharmacology in Psychiatry: From Molecular Studies to Clinical RealityFormat:PaperbackDimensions:329 pages, 23.5 × 15.5 × 0.07 inPublished:December 10, 2011Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:364274432X

ISBN - 13:9783642744327

Look for similar items by category:


Table of Contents

Strategies in Psychotropic Drug Innovation.- Receptor Subtypes and Endogenous Ligands: Rational Tools in the Search for Psychotropic Drugs?.- Histamine H3 Receptors in the Brain: Potent and Selective Ligands..- Targets for Neurotransmitter Receptor Research Using PET Scan: The Neuroleptic Binding Site..- The Potential of Positron-Emission Tomography for Pharmacokinetic and Pharmacodynamic Studies of Neuroleptics..- Neurotransmitter Interactions as a Target of Drug Action..- E-10-Hydroxynortriptyline: Effects and Disposition of a Potential Novel Antidepressant..- Molecular Graphics of Antidepressant Drugs and Metabolites..- Negative Symptoms in Schizophrenia: A Target for New Drug Development..- Clinical Significance of Receptor-Selective Drugs.- Clinical Effects of Selective Serotonin Reuptake Inhibitors..- Effects of Serotonergic Agonists on Neuroendocrine Responses of Rhesus Monkeys and Patients with Depression and Anxiety Disorders..- Theoretical and Practical Implications of a Controlled Trial of an ?2-Adrenoceptor Antagonist in the Treatment of Depression..- Selective Dopamine Dt and D2 Receptor Antagonists..- Animal Pharmacology of Raclopride, a Selective Dopamine D2 Antagonist..- Benzodiazepine Receptor Subtypes and Their Possible Clinical Significance..- Pharmacogenetics in Psychopharmacology.- Genetic Polymorphisms of Drug-Metabolizing Enzymes: Molecular Mechanisms..- Genetic Polymorphism in Drug Oxidation..- The Use of Human Liver Banks in Pharmacogenetic Research..- Inhibitors of the Microsomal Oxidation of Psychotropic Drugs: Selectivity and Clinical Significance..- Pharmacogenetics of Antidepressants..- Pharmacokinetic and Clinical Significance of Genetic Variability in Psychotropic Drug Metabolism..- Inhibition of Desipramine 2-Hydroxylation by Quinidine and Quinine in Rapid and Slow Debrisoquine Hydroxylators..- Debrisoquine Oxidation Phenotype in Psychiatric Patients..- Role of Pharmacogenetics in Drug Development..- Clinical Significance of Pharmacokinetic Variability.- Clinical Implications of the Pharmacokinetics of Tricyclic Antidepressants..- Detection of Populations at Risk Using Drug Monitoring Data..- Hydroxy Metabolites of Tricyclic Antidepressants: Evaluation of Relative Cardiotoxicity..- Therapeutic Drug Monitoring of Tricyclic Antidepressants: A Means of Avoiding Toxicity..- Neuroleptic Drug Levels in Erythrocytes and in Plasma: Implications for Therapeutic Drug Monitoring..- Active Metabolites of Neuroleptics in Plasma and CSF: Implications for Therapeutic Drug Monitoring..- Hydroxyhaloperidol and Clinical Outcome in Schizophrenia..- Plasma Level Monitoring for Maintenance Neuroleptic Therapy..- Perphenazine Serum Levels in Patients on Standard Doses..- Dose-Finding Problems with Psychotropic Drugs.- From Animal Experiments to Clinical Dosing: Some Aspects of Preclinical Development of Antidepressants..- Evaluation of Clinical and Biological Parameters in Healthy Volunteers: More than Pharmacokinetics and Side Effects?.- Dose Finding and Serum Concentrations of Neuroleptics in the Treatment of Schizophrenic Patients..- Post-Marketing Surveillance of Psychotropic Drugs..- List of Participants.